CHEK2 and cancer: In fact, while the clinical significance of the majority of genetic and epigenetic changes we were able to assess remains undetermined, this strategy allowed the identification of loss-of-function mutations in CHEK2, a gene previously reported to be involved in susceptibility to cancers of different organs, including breast, colorectum and prostate [40–42].